Aromatic-Cationic Peptides for SERCA2a Stabilization in Myocardial Infarction
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Following myocardial infarction, left ventricular remodeling leads to dilation, heart failure, and increased oxygen demand, with decreased expression of sarco/endoplasmic reticulum Ca2+-ATPase 2a (SERCA2a), contributing to progressive ventricular dilation and hypertrophy, ultimately predicting death.
Innovation Solution
Administration of therapeutically effective amounts of aromatic-cationic peptides, such as D-Arg-2′6′-Dmt-Lys-Phe-NH2, to normalize and stabilize SERCA2a expression in mammalian subjects, thereby preventing or treating left ventricular remodeling.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Productivity
If conventional treatment is applied after myocardial infarction, then initial compensation for reduced stroke volume occurs through left ventricular dilation, but progressive dilatation and hypertrophy eventually lead to congestive heart failure
Solution Approach 1:
Instead of allowing the natural compensatory dilation process to proceed unchecked, the invention reverses the approach by administering aromatic-cationic peptides that actively counteract dilation and promote ventricular remodeling reversal, thereby preventing the progression to heart failure while maintaining adequate stroke volume
Solution Approach 2:
The invention changes the physiological parameters of the left ventricle by administering aromatic-cationic peptides that modify calcium handling through SERCA2a upregulation, altering the balance between dilation and contraction to prevent progressive dilatation while maintaining cardiac output
2Productivity
If left ventricular dilation occurs to compensate for reduced stroke volume, then initial compensation is achieved, but progressive dilatation increases wall stress and oxygen demand leading to heart failure
Solution Approach 1:
The invention applies preliminary action by administering aromatic-cationic peptides early after myocardial infarction to prevent the development of pathological dilation and hypertrophy before they occur, thereby avoiding the subsequent increase in wall stress and oxygen demand that would result from progressive remodeling
Solution Approach 2:
Rather than allowing compensatory dilation to proceed and then treating the consequences, the invention inverts the approach by actively preventing dilation through SERCA2a-mediated calcium reuptake enhancement, thereby maintaining lower wall stress and oxygen demand while preserving stroke volume
3Stability of the object's composition
If SERCA2a expression is decreased following myocardial infarction, then calcium reuptake is impaired contributing to ventricular dilation, but restoring SERCA2a expression requires novel therapeutic approaches
Solution Approach 1:
The invention uses aromatic-cationic peptides as intermediary molecules that bind to and stabilize SERCA2a, enhancing its expression and function without requiring complex gene therapy vectors or cellular manipulation, thereby simplifying the therapeutic approach while effectively restoring calcium reuptake
Solution Approach 2:
The invention changes the molecular parameters of SERCA2a by administering aromatic-cationic peptides that directly interact with the protein, stabilizing its structure and enhancing its expression levels, thereby restoring calcium handling function through a simple pharmacological intervention rather than complex therapeutic procedures
Data Source
AI summary
The disclosure provides methods and compositions for increasing SERCA2a expression levels in a mammalian subject in need thereof. The methods comprise administering to the subject a therapeutic amount of an aromatic-cationic peptide to subjects in need thereof. In some embodiments, the aromatic-cationic peptide is D-Arg-2′6′-Dmt-Lys-Phe-NH2, or a pharmaceutically acceptable salt thereof such as acetate or trifluoroacetate salt. In some embodiments, the subject has suffered a myocardial infarction.